PLAT and ischemic stroke: tPA is the sole FDA-approved thrombolytic agent for addressing thrombosed vessels, yet its application is limited to a small portion of patients due to a narrow treatment window of up to 3 h, along with notable side effects such as the potential conversion of an ischemic stroke to a hemorrhagic one and several contraindications.